Belite Bio Inc ADR (BLTE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Belite Bio Inc ADR (BLTE) has a cash flow conversion efficiency ratio of 0.000x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.38K) by net assets ($770.49 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Belite Bio Inc ADR for the company's overall valuation and market capitalisation.
Belite Bio Inc ADR - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how Belite Bio Inc ADR's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Belite Bio Inc ADR Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Belite Bio Inc ADR ranked by their cash flow conversion efficiency. See BLTE operating cash flow to total debt to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Covivio SA
PA:COV
|
0.033x |
|
Clal Insurance Enterprises Holdings Ltd
TA:CLIS
|
-0.068x |
|
Rayonier Inc
NYSE:RYN
|
0.116x |
|
Coromandel International Limited
NSE:COROMANDEL
|
0.150x |
|
GPT Group
AU:GPT
|
0.035x |
|
Ford Otomotiv Sanayi AS
IS:FROTO
|
0.212x |
|
thyssenkrupp AG
F:TKA1
|
-0.120x |
|
United Integrated Services Co Ltd
TW:2404
|
0.448x |
Annual Cash Flow Conversion Efficiency for Belite Bio Inc ADR (2020–2025)
The table below shows the annual cash flow conversion efficiency of Belite Bio Inc ADR from 2020 to 2025. View BLTE live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $770.49 Million | $-36.99 Million | -0.048x | +76.05% |
| 2024-12-31 | $145.82 Million | $-29.23 Million | -0.200x | +39.24% |
| 2023-12-31 | $90.43 Million | $-29.84 Million | -0.330x | -19.51% |
| 2022-12-31 | $41.50 Million | $-11.46 Million | -0.276x | -155.75% |
| 2021-12-31 | $-15.09 Million | $-7.47 Million | 0.495x | -21.55% |
| 2020-12-31 | $-7.04 Million | $-4.44 Million | 0.631x | -- |
About Belite Bio Inc ADR
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and … Read more